Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376817 | 0.91 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2369827 | 0.87 | MEN1 (0.57) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL92054 | 0.86 | KMT2A (0.62) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL504454 | 0.83 | MEN1 (0.68) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1000788 | 0.83 | MEN1 (0.71) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL5109854 | 0.83 | MEN1 (0.71) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7424105 | 0.83 | MEN1 (0.71) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4710641 | 0.82 | MEN1 (0.69) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL794423 | 0.82 | MEN1 (0.69) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL16611411 | 0.82 | MEN1 (0.69) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981969-B2 | Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug | MERCK SHARP & DOHME CORP. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9873671-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873671-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170015629-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-01-19 | — | — | US | disclosed |
| US-20170015629-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-01-19 | — | — | US | disclosed |
| US-9505722-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505722-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9339510-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9339510-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160108048-A1 | IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2016-04-21 | — | — | US | disclosed |
| WO-2003026770-A1 | METHOD FOR REMOVING METAL FROM THE PRODUCTS OF OLEFIN METATHESIS REACTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003024924-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-6534498-B1 | Compound which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a factor. | SMITHKLINE BEECHAM CORPORATION | 2003-03-18 | — | — | US | disclosed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1231923-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
| WO-2001034157-A9 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001034157-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | MEN1 3024/4885KMT2A 1833/4885NPSR1 1684/4885 |
| US-20170015629-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | MEN1 3142/4885KMT2A 3876/4885NPSR1 3654/4885 |
| US-20160108048-A1 | IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | CYP3A43, CYP3A4, CYP3A7 | MEN1 3863/4885KMT2A 1824/4885NPSR1 1289/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | MEN1 2054/4885KMT2A 2920/4885NPSR1 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.